Compare Aurobindo Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs STERLING BIOTECH - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA STERLING BIOTECH AUROBINDO PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 11.0 -0.4 - View Chart
P/BV x 2.4 0.0 16,756.8% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 AUROBINDO PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
STERLING BIOTECH
Dec-13
AUROBINDO PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs80911 7,704.8%   
Low Rs5043 14,823.5%   
Sales per share (Unadj.) Rs281.126.8 1,048.5%  
Earnings per share (Unadj.) Rs41.4-15.0 -276.5%  
Cash flow per share (Unadj.) Rs50.9-5.5 -931.4%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.454.9 363.3%  
Shares outstanding (eoy) m585.88267.87 218.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.30.3 900.9%   
Avg P/E ratio x15.9-0.5 -3,416.3%  
P/CF ratio (eoy) x12.9-1.3 -1,014.2%  
Price / Book Value ratio x3.30.1 2,600.3%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,6301,862 20,660.2%   
No. of employees `00017.31.4 1,280.1%   
Total wages/salary Rs m21,308547 3,896.9%   
Avg. sales/employee Rs Th9,500.75,303.3 179.1%   
Avg. wages/employee Rs Th1,229.4403.8 304.4%   
Avg. net profit/employee Rs Th1,397.9-2,959.0 -47.2%   
INCOME DATA
Net Sales Rs m164,6667,181 2,293.2%  
Other income Rs m1,02043 2,393.9%   
Total revenues Rs m165,6867,223 2,293.8%   
Gross profit Rs m37,718947 3,983.3%  
Depreciation Rs m5,5802,543 219.4%   
Interest Rs m7774,377 17.8%   
Profit before tax Rs m32,380-5,931 -546.0%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,183-1,924 -425.2%   
Profit after tax Rs m24,229-4,007 -604.7%  
Gross profit margin %22.913.2 173.7%  
Effective tax rate %25.332.4 77.9%   
Net profit margin %14.7-55.8 -26.4%  
BALANCE SHEET DATA
Current assets Rs m121,87814,335 850.2%   
Current liabilities Rs m86,80649,809 174.3%   
Net working cap to sales %21.3-494.0 -4.3%  
Current ratio x1.40.3 487.9%  
Inventory Days Days130403 32.2%  
Debtors Days Days68171 40.1%  
Net fixed assets Rs m81,03755,432 146.2%   
Share capital Rs m586268 218.7%   
"Free" reserves Rs m116,21813,935 834.0%   
Net worth Rs m116,80414,701 794.5%   
Long term debt Rs m4,5129,478 47.6%   
Total assets Rs m211,05273,988 285.3%  
Interest coverage x42.7-0.4 -12,019.0%   
Debt to equity ratio x00.6 6.0%  
Sales to assets ratio x0.80.1 803.9%   
Return on assets %11.80.5 2,365.5%  
Return on equity %20.7-27.3 -76.1%  
Return on capital %27.4-6.4 -425.7%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m80,7271,860 4,340.6%   
Fx outflow Rs m34,70025 139,414.6%   
Net fx Rs m46,0271,835 2,508.4%   
CASH FLOW
From Operations Rs m19,5481,719 1,137.4%  
From Investments Rs m-19,570-3,148 621.6%  
From Financial Activity Rs m8,6421,426 606.0%  
Net Cashflow Rs m8,922-3 -262,414.7%  

Share Holding

Indian Promoters % 54.1 33.9 159.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.0 -  
FIIs % 27.7 9.9 279.8%  
ADR/GDR % 0.0 16.9 -  
Free float % 10.2 39.3 26.0%  
Shareholders   69,601 21,482 324.0%  
Pledged promoter(s) holding % 8.6 55.9 15.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS